Payment overview · 2025
General Payments
$2,353.28
110 reported records · 15 companies
Healthcare provider profile · identity verified
Jon Mitchell Twining, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · MYRTLE BEACH, SC · NPI 1568492346
Verified facts
What the public records show
CMS Open Payments records show Jon Mitchell Twining, MD received $2,353.28 in general payments during 2025 across 110 reported records.
ABBVIE INC. accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $856.38 | 36.4% | 40 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $316.88 | 13.5% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $310.32 | 13.2% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $155.59 | 6.6% | 9 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.97 | 6.4% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.83 | 5.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.30 | 4.0% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $90.80 | 3.9% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $63.04 | 2.7% | 3 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $58.50 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.06 | 1.3% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $30.01 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.35 | 0.9% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $20.30 | 0.9% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $15.95 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,276.29 | 109 |
| Education | $76.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $594.50 | 26 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $316.88 | 17 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $310.32 | 12 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $251.74 | 12 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $149.97 | 7 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $137.83 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $96.03 | 6 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $95.30 | 4 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $90.80 | 5 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $63.04 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $31.67 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $30.06 | 2 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $30.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $25.90 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $10.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $10.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 407 | 63 |
| Prednisone | Prednisone | 401 | 137 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 375 | 43 |
| Gabapentin | Gabapentin | 272 | 57 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 265 | 75 |
| Methotrexate | Methotrexate Sodium | 250 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 168 | 51 |
| Tramadol Hcl | Tramadol Hcl | 151 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 121 | 20 |
| Celecoxib | Celecoxib | 117 | 34 |
| Pregabalin | Pregabalin | 113 | 28 |
| Alprazolam | Alprazolam | 81 | 18 |
| Naproxen | Naproxen | 81 | 19 |
| Enbrel Sureclick | Etanercept | 69 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 67 | 21 |
| Folic Acid | Folic Acid | 63 | 18 |
| Azathioprine | Azathioprine | 62 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 60 | 21 |
| Trazodone Hcl | Trazodone Hcl | 59 | 19 |
| Allopurinol | Allopurinol | 55 | 14 |
| Pilocarpine Hcl | Pilocarpine Hcl | 55 | 23 |
| Risedronate Sodium | Risedronate Sodium | 53 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 17 |
| Leflunomide | Leflunomide | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 15 |
| Omeprazole | Omeprazole | 46 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 17 |
| Furosemide | Furosemide | 41 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 11 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Lisinopril | Lisinopril | 32 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Humira(Cf) Pen | Adalimumab | 31 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 12 |
| Meloxicam | Meloxicam | 29 | suppressed |
| Sulfasalazine | Sulfasalazine | 29 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Humira Pen | Adalimumab | 27 | suppressed |
| Rinvoq | Upadacitinib | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 15 |
| Famotidine | Famotidine | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 17 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Humira | Adalimumab | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Buprenorphine | Buprenorphine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Humira(Cf) | Adalimumab | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,353.28 · 110 records | ABBVIE INC. | Actemra, BENLYSTA, Bimzelx, COSENTYX, Kineret, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, OTEZLA, PANZYGA, PURIFIED CORTROPHIN GEL, QULIPTA, RINVOQ, SAPHNELO, SKYRIZI, TALTZ, TAVNEOS, TREMFYA, UBRELVY, UPLIZNA, VYALEV, VYVGART, VYVGART HYTRULO, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rinvoq play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error